Nathan Connell: Interesting Data in The Management of HAC Has Been Published in Blood from Benoit Guillet and Colleagues
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn:
”Interesting data in the management of hemophilia A Carriers (HAC) has been published in Blood from authors Benoit Guillet and colleagues
The article, “F8 gene variants influence the response to desmopressin in hemophilia A carriers,” provides crucial insights for clinical practice regarding the use of desmopressin to correct factor VIII (FVIII) levels in this population.
This large-scale study (n=361) leveraged a population pharmacokinetic/pharmacodynamic model to uncover key factors dictating treatment efficacy:
- Genotype Matters: The study found that HAC with null F8 gene variants exhibited a significantly poorer FVIII response to desmopressin, characterized by a lower mean peak FVIII level and higher FVIII clearance, compared to those with non-null variants.
- Body Weight Influence: Patients with a body weight <35 kg also showed a diminished response, including lower FVIII peaks and a shorter duration of FVIII:C levels ≥0.8 IU/mL.
These findings underscore the need for genotype-informed and weight-considered dosing strategies when utilizing desmopressin to move us toward a more personalized approach to managing bleeding in hemophilia A carriers.
Read the full article for a detailed analysis.”
Read the full article in Blood.
Article: F8 gene variants influence the response to desmopressin in hemophilia A carriers
Authors: Benoît Guillet Corresponding Author , Roseline D’Oiron, Marc Trossaert, Bénédicte Wibaut, Brigitte Pan-Petesch, Birgit Frotscher, Fabienne Genre-Volot, Laurent Ardillon, Stéphanie Desage, Céline Falaise, Christine Biron-Andreani, Vincent Cussac, Brigitte Tardy, Yoann Huguenin, Herve Chambost, Sophie Bayart, Sabine-Marie Castet, Xavier Delavenne

Stay updated on all scientific advances in the field of hemophilia with Hemostasis Today.
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026
-
Jul 14, 2026, 12:02Louise St. Germain Bannon: Our first ISTH regulatory session at ISTH 2026
-
Jul 14, 2026, 11:21Malwina Maliszewska: Advancing Coagulation Diagnostics at ISTH 2026
-
Jul 14, 2026, 11:07Mary Cushman: Honoring Outstanding Mentorship at ISTH 2026
-
Jul 14, 2026, 10:53Maha Othman: Advancing the Management of Inherited Thrombocytopenias at ISTH 2026